- within Law Department Performance topic(s)
- with Finance and Tax Executives and Inhouse Counsel
- in Europe
- with readers working within the Technology, Metals & Mining and Law Firm industries
Marshall Gerstein Partner Noah Tilton contributed a column to Life Science Leader discussing artificial intelligence's impact on the life science industry. With all the benefits of this emerging technology – such as drug discovery, clinical trials, and regulatory compliance – also come challenges for protecting intellectual property.
"AI implementation in life sciences raises various patent law considerations, including patent subject matter eligibility, novelty/obviousness, and sufficiency of disclosure," Noah wrote in describing the various obstacles innovators may face in protecting their IP.
Read Noah's solutions in his column in Life Science Leader.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
